Member Info for biffa

Fantastic news.
P11 is a winner.

Not sure anyone releases news at 2am! (USA time)
Should get an idea by midday if it's PDSB related which everything is pointing to.

If you have a look at the results and placing docs you come up with a slightly better NAV than the current SP. A lot will depend on PDSB, but as we stand this evening.

A couple of things to remember.

Only 15M shares in issue
Recent placing at 65p to buy EMV Capital.
Concert party hold more than 50% of the shares so limited free float if it starts to move.

EMV Capital portfolio £3.4M
Cash £1.5M
3 main holdings £1.1M (Cyto,Edibone,G-Tech)
Glycotest £5.0M (more now as we hold a higher %)
PDSB £3.25M @ $3.00 a share.
£14.25M
I can't find a value for Proaxis, 100% owned, but as it just won a £300K grant and has new sales deals for USA and a few other areas, lets say £3M.

Add in todays PDSB rise, which is another £650K and you get close to £18M.

M Cap today less than £7M.

PDSB has some near term news flow due over the next few months which could send it parabolic.

Discuss!

Quite a positive that they released this now, rather than in the trading update.

My point being, there must be enough decent 'other' news to come, that it's not needed!

Looks like a cure for cancer (in mice)
Every chance PDSB could go parabolic sometime this year.
Happy to keep adding NSCI at this price.

Finncap gave GDR a good write up in their life sciences blurb yesterday.
You would think Finncap and Peel Hunt would be able to place the last 5M? of BGFs holding between them!
Looking forward to some news next week.

The only NDA in place are the ones between DB/GDR and us poor shareholders!
Has anyone got any idea as to wtf is going on here?

Our BAMS test for sale. Has been for a while.

https://www.adeptrix.com/store#!/SARS-CoV-2-S1-Glycoprotein-Assay/p/234586062/category=0

However, click Bams Store and then 'Upcoming Products' and you have a brand new page of 60 new tests/assays!

Fits in with this weeks press releases. Let's hope we are involved in some of them.

Any idea on when the sh@tshow starts today?

FFS who gives a shot about B2B/B2C.
They just need to sell something!
Europe must be crying out for a test that works on the new Covid.

At least we are selling something at $1200 a pop!
Adeptrix.com/Bams store/Reagents/Featured Products
SARS-CoV-2 S1 Glycoprotein Assay

Product Details
The product is available to researchers involved in applying MALDI MS to viral typing. Contact us for additional details.

The kit contains high binding capacity magnetic beads conjugated to an Affimer® binder that recognizes an epitope within SARS-CoV-2 spike glycoprotein subunit 1 (S1 glycoprotein). The product is suitable for affinity precipitation and enrichment of native or recombinant SARS-CoV-2 spike glycoprotein. It may be also used for capturing intact virions containing the spike glycoprotein.

Whatever your view, there is no doubt that a pretty full update is overdue.

One could take the view that AS refusal to produce a '2nd rate test', 2 or 3 months ago, (one of his video updates) has already resulted in us missing out on £496M + £138M+all the rest that Innova have contracted, and a SP north of £10.

If nothing this week then you have to wonder if Smith and Wilson actually know they have shareholders?

43 Laboratory Mass spectrometry Validated as a part of a broader pilot (different validation route)

Game on.

The report is a great read.
The rubbish revs of £1M just about covers the BOD pay and bonus.
DB should be kicked out asap. (£480K)
A covid test that was first out of the gates in June ffs and they couldn't sell a single one.
Who has an AGM on Dec 30th. Priceless.

Good use of their cash to buy in 4 new product lines. R@D all done. Strip out costs,management,head office etc.

That govt link of the 22nd June and the later one saying we are in the mix.5 fooken months later and jack sh*t. WTF didn't we just produce a rubbish test like everyone else and make millions.Then bring out the brilliant 99%/99% upgrade and make even more money.I remember the AS video when he refused to bring out a 2nd rate test.Anyway, we are where we are, which only AS knows.(and i've been here from the start and hold 100k+, before anyone asks)

Talking of valuations, IP released this today.

It gives a market value of £1.7Billion to Oxford Nanopore!

All things being equal we should be worth that (and the rest) on confirmation of our first order. Approx £8.00 a share.

FOR RELEASE ON 13 October 2020

IP Group plc - Portfolio company Oxford Nanopore Technologies announces GBP84.4m of additional funding

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, notes that its portfolio company Oxford Nanopore Technologies Ltd ("Oxford Nanopore" or "the Company") has announced that it has raised an additional GBP84.4 million of new capital from existing and new investors including International Holdings Company (IHC) and RPMI Railpen.

The funds will be used to support the rapid acceleration of Oxford Nanopore's commercial and manufacturing operations as well as ongoing innovation in the field of nanopore technology. The round takes the amount raised this year by Oxford Nanopore to GBP162.1 million, following fund raisings in January and May of GBP29.3 million and GBP48.4 million respectively.

Following the capital raise, IP Group has a 15.0% undiluted beneficial stake in Oxford Nanopore, valued at GBP257.7 million. The directors will review the carrying value of Oxford Nanopore, as usual, as part of the Group's Annual Results for 2020 in light of this funding round and all other relevant information.

Last week, Oxford Nanopore announced that its LamPORE test is now CE marked for in vitro diagnostic use for the detection of the SARS-CoV-2 virus that causes COVID-19, using its GridION device. Its LamPORE test is now in the process of initial rollouts in the UK, Germany, Switzerland and the United Arab Emirates.

The Company previously announced that it had partnered with the UK's Department of Health and Social Care with an initial order of 450,000 LamPORE SARS-CoV-2 tests and the potential to increase to millions of tests per month as indicated by the recent publication of a contract award notice of GBP112.6m on the TED (Tenders Electronic Daily) website. Further regulatory approvals are being pursued in other countries, including Emergency Use Authorisation in the United States, and with its partner G42 in the United Arab Emirates.

Thank you for posting the other one.

If the above is to much to read on a Bank Holiday Monday, this one might get you opening the fizz!

Just take this as a read across to Avacta and times by ten!

Sona Nanotech press release May 22nd (3 days ago)

Sona has received expressions of interest for tens of millions of its a COVID-19 rapid detection, point-of-care, antigen test and has secured non-binding letters of intent for 4.7 million of its tests, subject to test performance parameters and pricing. The Company has begun technology transfer activities with secured manufacturers and expects to begin taking deposits on letters of intent and expressions of interest following the completion and publishing of the validation results.

The Company cautions that its test is still an unvalidated prototype and will update the market as appropriate.

I believe we are ahead of Sona.

Just take the 5 million letters of intent at say $30 a test gives you $150M on your first batch.

Fook me, where is the bottle opener!

I posted this on the 4D board but as pointed out by eeza, much the same story here.

Just to add a bit of reassurance to my co investors who are perhaps new to this game.

There is no doubt that Lansdowne Partners (they are just one of many 2nd rate hedge funds) are effectively a forced seller in 4D.

If you do some research on LP, you will see that they were doing badly before the March 20 collapse, but got absolutely hammered during the sell off.

Funds down from $13B in 2015 to $3B end of 2019, minus 30% return last year and then went into the March sh@t fest overweight in airline stocks!

They will have forced redemptions as investors pull out and will need liquidity to cover. (i.e., need to raise cash where they can)

Which brings us on to 4D.

There is obviously a buyer who is happy to take LP stock but on his terms.

Concentrate more on whose buying, rather than the seller.